A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination with Enzalutamide in Subjects with Metastatic Castrate-Resistanct Prostate Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
April 1, 2016
End Date
December 8, 2020
Administered By
Duke Cancer Institute
Awarded By
Gilead Sciences, Inc.
Start Date
April 1, 2016
End Date
December 8, 2020